Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 5/20 | 0.96 |
| ▸ | HTR7 known ✓ | P34969 | 3/20 | 0.71 |
| ▸ | HTR3A known ✓ | P46098 | 9/20 | 0.68 |
| ▸ | HTR1A known ✓ | P08908 | 8/20 | 0.68 |
| ▸ | HTR6 known ✓ | P50406 | 2/20 | 0.58 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 1/20 | 0.58 |
| ▸ | HTR3B known ✓ | O95264 | 1/20 | 0.58 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.58 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.58 |
| ▸ | HTR3D known ✓ | Q70Z44 | 1/20 | 0.58 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 1/20 | 0.58 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.58 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.55 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.55 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.55 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.55 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.55 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.55 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.55 |
| ▸ | HTR5A known ✓ | P47898 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30182987 | 1.00 | ADRB1 (0.96) | ADRB1HTR7HTR3AHTR1ACYP1A2 | |
| Hydrochloric Acid SCHEMBL314296 | 1.00 | ADRB1 (0.96) | ADRB1HTR7HTR3AHTR1ACYP1A2 | |
| Hydrochloric Acid SCHEMBL615079 | 1.00 | ADRB1 (0.96) | ADRB1HTR7HTR3AHTR1ACYP1A2 | |
| SCHEMBL2209183 | 0.98 | ADRB1 (1.00) | ADRB1HTR7HTR3AHTR1ACYP1A2 | |
| SCHEMBL4896 | 0.98 | ADRB1 (1.00) | ADRB1HTR7HTR3AHTR1ACYP1A2 | |
| SCHEMBL29432760 | 0.98 | ADRB1 (1.00) | ADRB1HTR7HTR3AHTR1ACYP1A2 | |
| Bromide SCHEMBL10672999 | 0.96 | ADRB1 (0.96) | ADRB1HTR7HTR3AHTR1ACYP1A2 | |
| Hydrochloric Acid SCHEMBL18043576 | 0.93 | ADRB1 (0.83) | ADRB1HTR7HTR3AHTR1ACYP1A2 | |
| SCHEMBL409069 | 0.91 | ADRB1 (0.86) | ADRB1HTR7HTR3AHTR1ACYP1A2 | |
| Bicarbonate SCHEMBL11622663 | 0.89 | ADRB1 (0.83) | ADRB1HTR7HTR3AHTR1ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-7002815-A | — | — | None | — | — | JP | disclosed |
| JP-5221968-A | — | — | None | — | — | JP | disclosed |
| CN-115894325-B | Derivative containing aryl piperazine structure, composition and application thereof | 徐州医科大学 | 2025-05-27 | — | — | CN | disclosed |
| US-20240368115-A1 | REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHUJING BIOPHARMA CO., LTD (CN) | 2024-11-07 | — | — | US | disclosed |
| EP-4382521-A1 | REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shujing Biopharma Co., Ltd (CN) | 2024-06-12 | — | — | EP | disclosed |
| CN-117946031-A | Substituted aromatic phenol derivatives of KNa1.1 channel inhibitors | 北京大学 | 2024-04-30 | — | — | CN | disclosed |
| CN-117769545-A | Tri-fused ring derivative-containing regulator, preparation method and application thereof | 上海枢境生物科技有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-115433116-B | Acylated indoline derivative, composition and application thereof | 徐州医科大学 | 2023-07-14 | — | — | CN | disclosed |
| WO-2023011608-A1 | REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海枢境生物科技有限公司 | 2023-02-09 | — | — | WO | disclosed |
| CN-109419802-B | Compounds having dopamine D3 receptor modulating activity and uses thereof | 中国人民解放军军事医学科学院毒物药物研究所（CN） | 2023-01-13 | — | — | CN | disclosed |
| EP-0532097-A1 | Piperazinyl(sulfon)amide derivatives of camphor as oxytocin antagonists | MERCK & CO. INC. (US) | 1993-03-17 | — | — | EP | disclosed |
| EP-0512755-A2 | Piperazine derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1992-11-11 | — | — | EP | disclosed |
| EP-0156331-B1 | BENZOFURAN DERIVATIVES, PROCESSES FOR PREPARING THE SAME AND ANTIHYPERTENSIVE AGENTS CONTAINING THE SAME | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1989-05-31 | — | — | EP | disclosed |
| US-4775757-A | CARDIOTONIC AND RENAL VASODILATING AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-10-04 | — | — | US | disclosed |
| US-4707550-A | N-(substituted thienyl)-N'-(substituted piperazinyl)-ureas | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-11-17 | — | — | US | disclosed |
| EP-0244176-A2 | Thienopyrimidine-2,4-dione derivatives and intermediates thereof | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-11-04 | — | — | EP | disclosed |
| US-4670560-A | VASODILATING AGENTS, HYPOTENSIVE AGENTS AND/OR CARDIOVASCULAR AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-06-02 | — | — | US | disclosed |
| US-4652566-A | (2-HYDROXY-3-(4-PHENYLPIPERAZINYL)PROPOXY) BENZOFURAN DERIVATIVES; DECREASED SIDE EFFECTS | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1987-03-24 | — | — | US | disclosed |
| EP-0156331-A2 | Benzofuran derivatives, processes for preparing the same and antihypertensive agents containing the same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1985-10-02 | — | — | EP | disclosed |
| US-4147869-A | ADRENERGIC BLOCKING AGENTS FOR TREATMENT OF ANGINA PECTORIS, ARRHYTHMIA AND HYPERTENSION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1979-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368115-A1 | REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | TPH1, TPH2, GAP43 | ADRB1 10/4885HTR7 18/4885HTR3A 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.